Life sciences VC investment group NetScientific plc (AIM: NSCI) on Tuesday reported positive data from its portfolio company, PDS Biotechnology Corporation (Nasdaq: PDSB), at the American Society for Radiation Oncology (ASTRO 2023) Annual Meeting. The IMMUNOCERV Phase 2 clinical trial evaluated PDS0101 in combination with standard-of-care chemoradiotherapy (CRT) for cervical cancer patients.

Patients treated with PDS0101 exhibited a rapid decline in circulating human papillomavirus (HPV) cell-free DNA (cfHPV-DNA) compared to standard-of-care (SOC) treatment. At week 5, clearance was 91.7% vs. 53.1% (P=0.0179).

The study, including 61 cervical cancer patients, showed promising results, correlating baseline cfDNA levels with cancer stage and lymph node involvement.

NetScientific continues to support PDS Biotech's progress in targeted cancer immunotherapies. The company manages an international portfolio of high-growth companies.

PDS Biotech is a clinical-stage immunotherapy company, developing targeted cancer and infectious disease immunotherapies based on proprietary T cell-activating platforms. PDS0101, its lead clinical candidate, has shown promise in reducing tumors and stabilizing disease in multiple Phase 2 clinical trials. The company plans a Phase 3 trial in combination with KEYTRUDA for recurrent/metastatic HPV16-positive head and neck cancer in 2023. PDS Biotech's immunotherapies aim to overcome current limitations by activating the right type, quantity and potency of T cells.